GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » OBI Pharma Inc (ROCO:4174) » Definitions » Revenue per Share

OBI Pharma (ROCO:4174) Revenue per Share : NT$0.30 (TTM As of Sep. 2024)


View and export this data going back to 2015. Start your Free Trial

What is OBI Pharma Revenue per Share?

OBI Pharma's revenue per share for the three months ended in Sep. 2024 was NT$0.10. OBI Pharma's revenue per share for the trailing twelve months (TTM) ended in Sep. 2024 was NT$0.30.

Warning Sign:

OBI Pharma Inc revenue per share has been in decline over the past 3 years.

During the past 12 months, the average Revenue Per Share Growth Rate of OBI Pharma was 194.20% per year. During the past 3 years, the average Revenue Per Share Growth Rate was -36.30% per year. During the past 5 years, the average Revenue Per Share Growth Rate was 3.90% per year. Please click Growth Rate Calculation Example (GuruFocus) to see how GuruFocus calculates Wal-Mart Stores Inc (WMT)'s revenue growth rate. You can apply the same method to get other companies' revenue growth rate.

The historical rank and industry rank for OBI Pharma's Revenue per Share or its related term are showing as below:

ROCO:4174' s 3-Year Revenue Growth Rate Range Over the Past 10 Years
Min: -62   Med: -10.2   Max: 604.1
Current: -36.3

During the past 13 years, OBI Pharma's highest 3-Year average Revenue Per Share Growth Rate was 604.10% per year. The lowest was -62.00% per year. And the median was -10.20% per year.

ROCO:4174's 3-Year Revenue Growth Rate is ranked worse than
86.03% of 759 companies
in the Biotechnology industry
Industry Median: 3.5 vs ROCO:4174: -36.30

OBI Pharma Revenue per Share Historical Data

The historical data trend for OBI Pharma's Revenue per Share can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

OBI Pharma Revenue per Share Chart

OBI Pharma Annual Data
Trend Dec14 Dec15 Dec16 Dec17 Dec18 Dec19 Dec20 Dec21 Dec22 Dec23
Revenue per Share
Get a 7-Day Free Trial Premium Member Only Premium Member Only 0.03 0.70 0.09 0.02 0.18

OBI Pharma Quarterly Data
Dec19 Mar20 Jun20 Sep20 Dec20 Mar21 Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23 Mar24 Jun24 Sep24
Revenue per Share Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 0.05 0.08 0.04 0.08 0.10

Competitive Comparison of OBI Pharma's Revenue per Share

For the Biotechnology subindustry, OBI Pharma's PS Ratio, along with its competitors' market caps and PS Ratio data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


OBI Pharma's PS Ratio Distribution in the Biotechnology Industry

For the Biotechnology industry and Healthcare sector, OBI Pharma's PS Ratio distribution charts can be found below:

* The bar in red indicates where OBI Pharma's PS Ratio falls into.



OBI Pharma Revenue per Share Calculation

Revenue per Share is the amount of Revenue per outstanding share of the company's stock.

Also referred as sales, revenue is income that a company receives from its normal business activities, usually from the sale of goods and services to customers. Revenue is often referred to as the "top line" due to its position on the income statement at the very top.

OBI Pharma's Revenue Per Share for the fiscal year that ended in Dec. 2023 is calculated as

Revenue Per Share (A: Dec. 2023 )=Revenue (A: Dec. 2023 )/Shares Outstanding (Diluted Average) (A: Dec. 2023 )
=41.549/230.411
=0.18

OBI Pharma's Revenue Per Share for the quarter that ended in Sep. 2024 is calculated as

Revenue Per Share (Q: Sep. 2024 )=Revenue (Q: Sep. 2024 )/Shares Outstanding (Diluted Average) (Q: Sep. 2024 )
=22.979/230.121
=0.10

Revenue per Share for the trailing twelve months (TTM) ended in Sep. 2024 adds up the quarterly data reported by the company within the most recent 12 months, which was NT$0.30

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.


OBI Pharma  (ROCO:4174) Revenue per Share Explanation

In ranking the predictability, companies with more consistent revenue and earnings growth are ranked high with predictability.

Peter Lynch categorized companies according to their revenue growth:

Slow Grower: Inflation < 10-Year Revenue Growth Rate < 10%:
Stalwart: 10% < 10-Year Revenue Growth Rate < 20%:
Fast Grower: 10-Year Revenue Growth Rate > 20%:

His favorite companies are stalwart, those growing between 10-20% a year.

Companies in cyclical industries may see their revenue fluctuate wildly in good years and bad years.


Be Aware

Revenue can be manipulated by changing the way how revenue is booked. Companies may book sales before the payment is received, or before the revenue is fully earned. These will be added to balance sheet items such as account payable or account receivables.


OBI Pharma Revenue per Share Related Terms

Thank you for viewing the detailed overview of OBI Pharma's Revenue per Share provided by GuruFocus.com. Please click on the following links to see related term pages.


OBI Pharma Business Description

Traded in Other Exchanges
N/A
Address
No. 3, Park Street, Room 1907, 19th Floor, Nangang District, Taipei, TWN, 115
OBI Pharma Inc is part of the healthcare sector. The company and its subsidiaries are engaged in new drug research. Its focus is on the unmet medical need in challenging diseases throughout the world, such as cancer. OBI strives to improve health and the quality of life through cost-effective therapeutics. The group has four reportable segments, which are the anti-cancer new drug segment, bispecific monoclonal antibody new drug segment, botulinum toxin new drug segment, and CDMO segment.

OBI Pharma Headlines

No Headlines